US5849769A
(en)
*
|
1994-08-24 |
1998-12-15 |
Medivir Ab |
N-arylalkyl-N-heteroarylurea and guandine compounds and methods of treating HIV infection
|
JP4959049B2
(ja)
|
1997-08-22 |
2012-06-20 |
アストラゼネカ・ユーケイ・リミテッド |
血管新生阻害剤としてのオキシインドリルキナゾリン誘導体
|
UA60365C2
(ru)
*
|
1998-06-04 |
2003-10-15 |
Пфайзер Продактс Інк. |
Производные изотиазола, способ их получения, фармацевтическая композиция и способ лечения гиперпролиферативного заболевания у млекопитающего
|
CA2359244C
(en)
|
1999-01-13 |
2013-10-08 |
Bayer Corporation |
.omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
EP1169038B9
(en)
|
1999-04-15 |
2013-07-10 |
Bristol-Myers Squibb Company |
Cyclic protein tyrosine kinase inhibitors
|
US7125875B2
(en)
|
1999-04-15 |
2006-10-24 |
Bristol-Myers Squibb Company |
Cyclic protein tyrosine kinase inhibitors
|
HN2000000051A
(es)
*
|
1999-05-19 |
2001-02-02 |
Pfizer Prod Inc |
Derivados heterociclicos utiles como agentes anticancerosos
|
US7078536B2
(en)
|
2001-03-14 |
2006-07-18 |
Genesoft Pharmaceuticals, Inc. |
Charged compounds comprising a nucleic acid binding moiety and uses therefor
|
CN1427839A
(zh)
|
2000-03-16 |
2003-07-02 |
根索福特股份有限公司 |
含有核酸结合部分的带电荷化合物及其用途
|
MXPA03001189A
(es)
|
2000-08-09 |
2004-05-14 |
Agouron Pharma |
Compuestos de pirazol-tiazol, composiciones farmaceuticas que los contienen y su uso para inhibir las cinasas dependientes de ciclinas.
|
ATE357444T1
(de)
|
2000-08-17 |
2007-04-15 |
Lumera Corp |
Design und synthese von nlo-materialien für electro-optische anwendungen, die von thiophen abgeleitet sind
|
ATE295354T1
(de)
|
2000-08-18 |
2005-05-15 |
Agouron Pharma |
Heterozyklische-hydroximino-fluorene und ihre verwendung zur inhibierung von proteinkinasen
|
KR100589032B1
(ko)
|
2000-10-20 |
2006-06-14 |
에자이 가부시키가이샤 |
질소 함유 방향환 유도체
|
NZ525788A
(en)
*
|
2000-11-28 |
2004-11-26 |
Pfizer Prod Inc |
Salts of a isothiazole-4-carboxamide and their use as anti-hyperproliferation agents
|
DK2311825T3
(en)
|
2000-12-21 |
2016-01-18 |
Novartis Ag |
Pyrimidinamines AS ANGIOGENESEMODULATORER
|
NZ569856A
(en)
|
2001-01-05 |
2010-03-26 |
Pfizer |
Antibodies to insulin-like growth factor 1 receptor
|
US6699866B2
(en)
|
2001-04-17 |
2004-03-02 |
Sepracor Inc. |
Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof
|
WO2003000194A2
(en)
|
2001-06-21 |
2003-01-03 |
Pfizer Inc. |
Thienopyridine and thienopyrimidine anticancer agents
|
HN2002000156A
(es)
|
2001-07-06 |
2003-11-27 |
Inc Agouron Pharmaceuticals |
Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
|
US7265134B2
(en)
|
2001-08-17 |
2007-09-04 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
US20030143165A1
(en)
*
|
2002-01-25 |
2003-07-31 |
Allan Evans |
NSAID-containing topical formulations that demonstrate chemopreventive activity
|
US20040023961A1
(en)
*
|
2002-02-11 |
2004-02-05 |
Bayer Corporation |
Aryl ureas with raf kinase and angiogenisis inhibiting activity
|
JP4636486B2
(ja)
|
2002-02-11 |
2011-02-23 |
バイエル、ファーマシューテイカルズ、コーポレイション |
脈管形成阻害活性を有するアリール尿素
|
WO2003068229A1
(en)
|
2002-02-11 |
2003-08-21 |
Bayer Pharmaceuticals Corporation |
Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
|
JP2005530745A
(ja)
|
2002-05-02 |
2005-10-13 |
メルク エンド カムパニー インコーポレーテッド |
チロシンキナーゼ阻害剤
|
US6989451B2
(en)
*
|
2002-06-04 |
2006-01-24 |
Valeant Research & Development |
Heterocyclic compounds and uses thereof
|
WO2003105843A1
(en)
*
|
2002-06-13 |
2003-12-24 |
Kinetek Pharmaceuticals, Inc. |
Methods of using isothiazole derivatives to treat cancer or inflammation
|
KR101116627B1
(ko)
|
2002-06-27 |
2012-10-09 |
노보 노르디스크 에이/에스 |
치료제로서 아릴 카르보닐 유도체
|
WO2004011461A1
(en)
*
|
2002-07-25 |
2004-02-05 |
Pfizer Products Inc. |
Isothiazole derivatives useful as anticancer agents
|
EP1539151B1
(en)
|
2002-08-02 |
2009-03-18 |
Genesoft Pharmaceuticals, Inc. |
Biaryl compounds having anti-infective activity
|
RS20050106A
(en)
*
|
2002-08-19 |
2007-11-15 |
Pfizer Products Inc., |
Combination therapy for hyperproliferative diseases
|
CA2503119A1
(en)
|
2002-10-25 |
2004-05-13 |
Genesoft Pharmaceuticals, Inc. |
Anti-infective biaryl compounds
|
JP2006509027A
(ja)
|
2002-12-10 |
2006-03-16 |
オーシェント ファーマシューティカルズ コーポレーション |
(ピロールカルボキサミド)−(ベンズアミド)−(イミダゾールカルボキサミド)モチーフを有する抗菌化合物
|
BR0317548A
(pt)
|
2002-12-19 |
2005-11-22 |
Pfizer |
Compostos de indazole e composições farmacêuticas para a inibição de proteìnas-cinases e métodos para o seu uso
|
WO2004067530A1
(en)
*
|
2003-01-27 |
2004-08-12 |
Pfizer Products Inc. |
Isothiazole derivatives
|
UY28213A1
(es)
|
2003-02-28 |
2004-09-30 |
Bayer Pharmaceuticals Corp |
Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
|
EP2617419A1
(en)
|
2003-04-24 |
2013-07-24 |
Incyte Corporation |
Aza spiro alkane derivatives as inhibitors of metallproteases
|
ATE366108T1
(de)
|
2003-05-20 |
2007-07-15 |
Bayer Pharmaceuticals Corp |
Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten
|
KR20110129988A
(ko)
|
2003-07-18 |
2011-12-02 |
암젠 인코포레이티드 |
간세포 성장인자에 결합하는 특이 결합제
|
PL1663978T3
(pl)
|
2003-07-23 |
2008-04-30 |
Bayer Healthcare Llc |
Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
WO2005044788A1
(ja)
|
2003-11-11 |
2005-05-19 |
Eisai Co., Ltd. |
ウレア誘導体およびその製造方法
|
MXPA06007667A
(es)
|
2004-01-06 |
2006-09-01 |
Novo Nordisk As |
Heteroaril-ureas y su uso como activadores de glucocinasa.
|
ES2246687B2
(es)
*
|
2004-02-11 |
2006-11-16 |
Miguel Muñoz Saez |
Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales.
|
WO2005081997A2
(en)
*
|
2004-02-20 |
2005-09-09 |
The Scripps Research Institute |
Isothiazole based protein kinase inhibitors
|
WO2005102327A1
(en)
*
|
2004-04-20 |
2005-11-03 |
Pfizer Products Inc. |
Dosage forms and methods of treatment using vegfr inhibitors
|
MXPA06012394A
(es)
|
2004-04-30 |
2007-01-31 |
Bayer Pharmaceuticals Corp |
Derivados de pirazolilurea sustituidos utiles en el tratamiento de cancer.
|
TW200538104A
(en)
*
|
2004-05-17 |
2005-12-01 |
Pfizer Prod Inc |
Phenyl derivatives for the treatment of abnormal cell growth
|
BRPI0514667A
(pt)
*
|
2004-08-26 |
2008-06-17 |
Pfizer Prod Inc |
processos para a preparação de derivados de isotiazol
|
RS51362B
(en)
|
2004-08-26 |
2011-02-28 |
Pfizer Inc. |
ENANTIOMERALLY PURE AMINOHETEROARYL UNITS AS PROTEIN KINASE INHIBITORS
|
EP2364699A1
(en)
|
2004-09-13 |
2011-09-14 |
Eisai R&D Management Co., Ltd. |
Joint use of sulfonamide based compound with angiogenesis inhibitor
|
US8772269B2
(en)
|
2004-09-13 |
2014-07-08 |
Eisai R&D Management Co., Ltd. |
Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
|
ES2322175T3
(es)
|
2004-09-17 |
2009-06-17 |
EISAI R&D MANAGEMENT CO., LTD. |
Composicion medicinal con estabilidad mejorada y gelificacion reducida.
|
EP1827434B1
(en)
|
2004-11-30 |
2014-01-15 |
Amgen Inc. |
Quinolines and quinazoline analogs and their use as medicaments for treating cancer
|
US7429667B2
(en)
|
2005-01-20 |
2008-09-30 |
Ardea Biosciences, Inc. |
Phenylamino isothiazole carboxamidines as MEK inhibitors
|
ATE477495T1
(de)
|
2005-03-16 |
2010-08-15 |
Osi Pharm Inc |
Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor
|
US20060216288A1
(en)
*
|
2005-03-22 |
2006-09-28 |
Amgen Inc |
Combinations for the treatment of cancer
|
BRPI0609655A2
(pt)
|
2005-03-31 |
2010-03-16 |
Agensys Inc |
anticorpos e moléculas relacionadas que ligam-se às proteìnas 161p2f10b
|
AU2006238930B2
(en)
|
2005-04-26 |
2010-12-23 |
Pfizer Inc. |
P-cadherin antibodies
|
KR20080024211A
(ko)
|
2005-07-08 |
2008-03-17 |
노보 노르디스크 에이/에스 |
디시클로알킬 우레아 글루코키나제 활성제
|
EP1925676A4
(en)
|
2005-08-02 |
2010-11-10 |
Eisai R&D Man Co Ltd |
TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
|
ES2546069T3
(es)
|
2005-09-07 |
2015-09-18 |
Amgen Fremont Inc. |
Anticuerpos monoclonales humanos para quinasa-1 de tipo receptor de activina (ALK-1)
|
WO2007035744A1
(en)
|
2005-09-20 |
2007-03-29 |
Osi Pharmaceuticals, Inc. |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
US20080108664A1
(en)
|
2005-12-23 |
2008-05-08 |
Liu Belle B |
Solid-state form of AMG 706 and pharmaceutical compositions thereof
|
AR059066A1
(es)
*
|
2006-01-27 |
2008-03-12 |
Amgen Inc |
Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
|
EP1987023B1
(en)
*
|
2006-02-10 |
2010-11-24 |
Amgen, Inc |
Hydrate forms of amg706
|
US7842836B2
(en)
|
2006-04-11 |
2010-11-30 |
Ardea Biosciences |
N-aryl-N'alkyl sulfamides as MEK inhibitors
|
MX2008013097A
(es)
*
|
2006-04-18 |
2008-10-27 |
Ardea Biosciences Inc |
Piridona sulfonamidas y piridona sulfamidas como inhibidores de metiletilcetona.
|
EP2021338A1
(en)
|
2006-05-09 |
2009-02-11 |
Pfizer Products Inc. |
Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
|
CN104706637A
(zh)
|
2006-05-18 |
2015-06-17 |
卫材R&D管理有限公司 |
针对甲状腺癌的抗肿瘤剂
|
US7910108B2
(en)
*
|
2006-06-05 |
2011-03-22 |
Incyte Corporation |
Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
|
DK2076502T3
(da)
*
|
2006-06-08 |
2011-07-25 |
Lilly Co Eli |
Substituerede carboxamider som antagonister af gruppe-1 metabotrope receptorer
|
US7932390B2
(en)
|
2006-06-29 |
2011-04-26 |
Hoffman-La Roche Inc. |
Substituted thieno[3,2-C]pyridine carboxylic acid derivatives
|
US8217177B2
(en)
|
2006-07-14 |
2012-07-10 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
PE20121506A1
(es)
|
2006-07-14 |
2012-11-26 |
Amgen Inc |
Compuestos triazolopiridinas como inhibidores de c-met
|
CN101511793B
(zh)
|
2006-08-28 |
2011-08-03 |
卫材R&D管理有限公司 |
针对未分化型胃癌的抗肿瘤剂
|
AU2007338792B2
(en)
|
2006-12-20 |
2012-05-31 |
Amgen Inc. |
Substituted heterocycles and methods of use
|
ES2449482T3
(es)
|
2007-01-09 |
2014-03-19 |
Amgen Inc. |
Derivados de bis-aril-amida útiles para el tratamiento de cáncer
|
US8962655B2
(en)
|
2007-01-29 |
2015-02-24 |
Eisai R&D Management Co., Ltd. |
Composition for treatment of undifferentiated gastric cancer
|
AU2008219166B2
(en)
|
2007-02-16 |
2013-05-16 |
Amgen Inc. |
Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors
|
KR20090115749A
(ko)
*
|
2007-02-26 |
2009-11-05 |
산텐 세이야꾸 가부시키가이샤 |
우레이드기와 아미노카르보닐기를 치환기로서 갖는 신규 피롤 유도체
|
US20100255004A1
(en)
*
|
2007-04-13 |
2010-10-07 |
Dana Farber Cancer Institute |
Receptor tyrosine kinase profiling
|
WO2008127710A2
(en)
|
2007-04-13 |
2008-10-23 |
Dana Farber Cancer Institute |
Methods for treating cancer resistant to erbb therapeutics
|
US8509487B2
(en)
*
|
2007-04-19 |
2013-08-13 |
Avago Technologies General Ip (Singapore) Pte. Ltd. |
System and method for optically measuring a parameter of an object
|
MX2010001636A
(es)
|
2007-08-14 |
2010-03-15 |
Hoffmann La Roche |
Derivados de pirazolo[3,4-d]-pirimidina como agentes antiproliferativos.
|
DK2188313T3
(en)
|
2007-08-21 |
2017-12-11 |
Amgen Inc |
HUMAN C-FMS ANTI-BINDING PROTEINS
|
AU2008325608B2
(en)
|
2007-11-09 |
2013-03-14 |
Eisai R & D Management Co., Ltd. |
Combination of anti-angiogenic substance and anti-tumor platinum complex
|
US20100029491A1
(en)
*
|
2008-07-11 |
2010-02-04 |
Maike Schmidt |
Methods and compositions for diagnostic use for tumor treatment
|
BRPI0918211A2
(pt)
|
2008-12-23 |
2015-12-08 |
Genentech Inc |
métodos de identificação de um paciente, métodos de predição da responsividade de um paciente, métodos de monitoramento, métodos de otimização da eficácia terapêutica e kit para detecção do níveis de expressão de p1gf
|
US20120189641A1
(en)
|
2009-02-25 |
2012-07-26 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
EP2400990A2
(en)
|
2009-02-26 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
In situ methods for monitoring the emt status of tumor cells in vivo
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
EP2401613A2
(en)
|
2009-02-27 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
EP2401614A1
(en)
|
2009-02-27 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
WO2010111254A1
(en)
|
2009-03-25 |
2010-09-30 |
Genentech, Inc. |
Novel anti-alpha5beta1 antibodies and uses thereof
|
AU2010273585B2
(en)
|
2009-07-13 |
2015-04-23 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of cancer
|
JP2013500991A
(ja)
|
2009-07-31 |
2013-01-10 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
mTOR阻害剤および血管新生阻害剤併用療法
|
ES2530732T3
(es)
|
2009-09-17 |
2015-03-05 |
Hoffmann La Roche |
Procedimientos de diagnóstico para el cáncer de pulmón
|
WO2011073521A1
(en)
|
2009-12-15 |
2011-06-23 |
Petri Salven |
Methods for enriching adult-derived endothelial progenitor cells and uses thereof
|
MX361668B
(es)
|
2009-12-21 |
2018-12-11 |
Genentech Inc |
Formulación de anticuerpos.
|
EP3150610B1
(en)
|
2010-02-12 |
2019-07-31 |
Pfizer Inc |
Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
|
CA2783665A1
(en)
|
2010-03-03 |
2011-09-09 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
WO2011109572A2
(en)
|
2010-03-03 |
2011-09-09 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
WO2011153224A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of cancer
|
ES2695899T3
(es)
|
2010-06-16 |
2019-01-11 |
Univ Pittsburgh Commonwealth Sys Higher Education |
Anticuerpos contra endoplasmina y su uso
|
WO2011161217A2
(en)
|
2010-06-23 |
2011-12-29 |
Palacký University in Olomouc |
Targeting of vegfr2
|
ES2573515T3
(es)
|
2010-06-25 |
2016-06-08 |
Eisai R&D Management Co., Ltd. |
Agente antitumoral que emplea compuestos con efecto inhibitorio de cinasas combinados
|
EP3696195B1
(en)
|
2010-07-23 |
2024-02-14 |
Trustees of Boston University |
Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
|
WO2012042421A1
(en)
|
2010-09-29 |
2012-04-05 |
Pfizer Inc. |
Method of treating abnormal cell growth
|
US20120214830A1
(en)
|
2011-02-22 |
2012-08-23 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
GB201103578D0
(en)
|
2011-03-02 |
2011-04-13 |
Sabrepharm Ltd |
Dipyridinium derivatives
|
UA112539C2
(uk)
|
2011-03-03 |
2016-09-26 |
Новартіс Аг |
Спосіб одержання похідних 2-карбоксамідциклоаміносечовини
|
US8623885B2
(en)
|
2011-03-23 |
2014-01-07 |
Amgen Inc. |
Fused tricyclic dual inhibitors of CDK 4/6 and FLT3
|
US8962650B2
(en)
|
2011-04-18 |
2015-02-24 |
Eisai R&D Management Co., Ltd. |
Therapeutic agent for tumor
|
US9896730B2
(en)
|
2011-04-25 |
2018-02-20 |
OSI Pharmaceuticals, LLC |
Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
|
US9945862B2
(en)
|
2011-06-03 |
2018-04-17 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
|
JP6105578B2
(ja)
|
2011-07-21 |
2017-03-29 |
トレロ ファーマシューティカルズ, インコーポレイテッド |
複素環式プロテインキナーゼ阻害剤
|
US9745288B2
(en)
|
2011-08-16 |
2017-08-29 |
Indiana University Research And Technology Corporation |
Compounds and methods for treating cancer by inhibiting the urokinase receptor
|
ES2851602T3
(es)
|
2011-12-28 |
2021-09-08 |
Allergan Inc |
Derivados de 3-fenil-5-ureidoisotiazol-4-carboxamida como inhibidores de cinasa
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
CN103508961B
(zh)
|
2012-06-26 |
2015-07-22 |
中美冠科生物技术(太仓)有限公司 |
抗肿瘤药物
|
EP2890696A1
(en)
|
2012-08-29 |
2015-07-08 |
Amgen, Inc. |
Quinazolinone compounds and derivatives thereof
|
JP6243918B2
(ja)
|
2012-10-16 |
2017-12-06 |
トレロ ファーマシューティカルズ, インコーポレイテッド |
Pkm2調節因子およびそれらの使用方法
|
JPWO2014098176A1
(ja)
|
2012-12-21 |
2017-01-12 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
キノリン誘導体のアモルファス及びその製造方法
|
MY185551A
(en)
|
2013-03-13 |
2021-05-19 |
Genentech Inc |
Antibody formulations
|
TR201911151T4
(tr)
|
2013-03-14 |
2019-08-21 |
Tolero Pharmaceuticals Inc |
Jak2 ve alk2 inhibitörleri ve bunların kullanım yöntemleri.
|
PL2968650T3
(pl)
|
2013-03-14 |
2019-05-31 |
Panoptica Inc |
Preparaty do oczu do dostarczania leku do tylnego fragmentu oka
|
EP2997377B1
(en)
|
2013-05-14 |
2018-07-18 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
|
ES2727374T3
(es)
|
2014-04-04 |
2019-10-15 |
Crown Bioscience Inc Taicang |
Gen de fusión HNF4G-RSPO2
|
MX2017001980A
(es)
|
2014-08-28 |
2017-05-04 |
Eisai R&D Man Co Ltd |
Derivado de quinolina muy puro y metodo para su produccion.
|
AU2015318001B2
(en)
|
2014-09-15 |
2021-03-25 |
Genentech, Inc. |
Antibody formulations
|
NZ767710A
(en)
|
2014-09-17 |
2023-09-29 |
Panoptica Inc |
Ocular formulations for drug-delivery and protection of the anterior segment of the eye
|
US9353093B2
(en)
|
2014-10-07 |
2016-05-31 |
Allergan, Inc. |
Indole-1-carboxamides as kinase inhibitors
|
US9403803B2
(en)
|
2014-10-08 |
2016-08-02 |
Allergan, Inc. |
Indole-3-carboxamides as kinase inhibitors
|
US9371314B2
(en)
|
2014-10-09 |
2016-06-21 |
Allergan, Inc. |
Pyridyl benzothiophenes as kinase inhibitors
|
US9359336B2
(en)
|
2014-10-09 |
2016-06-07 |
Allergan, Inc. |
Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors
|
EP3233829B1
(en)
|
2014-12-18 |
2019-08-14 |
Pfizer Inc |
Pyrimidine and triazine derivatives and their use as axl inhibitors
|
JP7041515B2
(ja)
|
2015-01-08 |
2022-03-24 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
骨、骨髄、及び軟骨の誘導を提供する因子及び細胞
|
SG11201706630UA
(en)
|
2015-02-25 |
2017-09-28 |
Eisai R&D Man Co Ltd |
Method for suppressing bitterness of quinoline derivative
|
AU2015384801B2
(en)
|
2015-03-04 |
2022-01-06 |
Eisai R&D Management Co., Ltd. |
Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
|
AU2016252609B2
(en)
|
2015-04-20 |
2022-06-30 |
Sumitomo Pharma Oncology, Inc. |
Predicting response to alvocidib by mitochondrial profiling
|
PT3298021T
(pt)
|
2015-05-18 |
2019-08-05 |
Tolero Pharmaceuticals Inc |
Pró-fármacos de alvocidib possuindo biodisponibilidade aumentada
|
MX2017015896A
(es)
|
2015-06-16 |
2018-08-09 |
Eisai R&D Man Co Ltd |
Agente anticancerigeno.
|
JP7083497B2
(ja)
|
2015-08-03 |
2022-06-13 |
スミトモ ファーマ オンコロジー, インコーポレイテッド |
がんの処置のための併用療法
|
GB2543550A
(en)
|
2015-10-21 |
2017-04-26 |
Hox Therapeutics Ltd |
Peptides
|
US20180371551A1
(en)
|
2015-12-03 |
2018-12-27 |
Agios Pharmaceuticals, Inc. |
Mat2a inhibitors for treating mtap null cancer
|
WO2018094275A1
(en)
|
2016-11-18 |
2018-05-24 |
Tolero Pharmaceuticals, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
AU2017379847B2
(en)
|
2016-12-19 |
2022-05-26 |
Sumitomo Pharma Oncology, Inc. |
Profiling peptides and methods for sensitivity profiling
|
MX2019007643A
(es)
|
2016-12-22 |
2019-09-09 |
Amgen Inc |
Benzoisotiazol, isotiazolo[3,4-b]piridina, quinazolina, ftalazina, pirido[2,3-d]piridazina y derivados de pirido[2,3-d]pirimidina como inhibirores de kras g12c para tratar el cancer de pulmon, pancreatico o colorrectal.
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
CA3075046A1
(en)
|
2017-09-08 |
2019-03-14 |
Amgen Inc. |
Inhibitors of kras g12c and methods of using the same
|
US11497756B2
(en)
|
2017-09-12 |
2022-11-15 |
Sumitomo Pharma Oncology, Inc. |
Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
|
EP3788038B1
(en)
|
2018-05-04 |
2023-10-11 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
MX2020011582A
(es)
|
2018-05-04 |
2020-11-24 |
Amgen Inc |
Inhibidores de kras g12c y metodos para su uso.
|
MA52564A
(fr)
|
2018-05-10 |
2021-03-17 |
Amgen Inc |
Inhibiteurs de kras g12c pour le traitement du cancer
|
ES2938987T3
(es)
|
2018-06-01 |
2023-04-18 |
Amgen Inc |
Inhibidores de KRAS G12c y métodos de uso de los mismos
|
MA52780A
(fr)
|
2018-06-11 |
2021-04-14 |
Amgen Inc |
Inhibiteurs de kras g12c pour le traitement du cancer
|
WO2020050890A2
(en)
|
2018-06-12 |
2020-03-12 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
CN112040945A
(zh)
|
2018-06-12 |
2020-12-04 |
Vtv治疗有限责任公司 |
葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途
|
KR20210038906A
(ko)
|
2018-07-26 |
2021-04-08 |
스미토모 다이니폰 파마 온콜로지, 인크. |
비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제
|
JP2020090482A
(ja)
|
2018-11-16 |
2020-06-11 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
AU2019384118A1
(en)
|
2018-11-19 |
2021-05-27 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
KR20210099066A
(ko)
|
2018-12-04 |
2021-08-11 |
스미토모 다이니폰 파마 온콜로지, 인크. |
암의 치료를 위한 작용제로서 사용하기 위한 cdk9 억제제 및 그의 다형체
|
AU2019403486A1
(en)
|
2018-12-20 |
2021-06-24 |
Amgen Inc. |
KIF18A inhibitors
|
WO2020132649A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
CA3123044A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Heteroaryl amides useful as kif18a inhibitors
|
EP3897855B1
(en)
|
2018-12-20 |
2023-06-07 |
Amgen Inc. |
Kif18a inhibitors
|
WO2020167990A1
(en)
|
2019-02-12 |
2020-08-20 |
Tolero Pharmaceuticals, Inc. |
Formulations comprising heterocyclic protein kinase inhibitors
|
KR20210146287A
(ko)
|
2019-03-01 |
2021-12-03 |
레볼루션 메디슨즈, 인크. |
이환식 헤테로아릴 화합물 및 이의 용도
|
KR20210146288A
(ko)
|
2019-03-01 |
2021-12-03 |
레볼루션 메디슨즈, 인크. |
이환식 헤테로사이클릴 화합물 및 이의 용도
|
JP2022525149A
(ja)
|
2019-03-20 |
2022-05-11 |
スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド |
ベネトクラクスが失敗した急性骨髄性白血病(aml)の処置
|
MX2021011289A
(es)
|
2019-03-22 |
2021-11-03 |
Sumitomo Pharma Oncology Inc |
Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
WO2020236947A1
(en)
|
2019-05-21 |
2020-11-26 |
Amgen Inc. |
Solid state forms
|
WO2021026099A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
MX2022001302A
(es)
|
2019-08-02 |
2022-03-02 |
Amgen Inc |
Inhibidores de kif18a.
|
WO2021026098A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
CA3147451A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
JP2022552873A
(ja)
|
2019-10-24 |
2022-12-20 |
アムジエン・インコーポレーテツド |
がんの治療におけるkras g12c及びkras g12d阻害剤として有用なピリドピリミジン誘導体
|
JP2022553857A
(ja)
|
2019-11-04 |
2022-12-26 |
レボリューション メディシンズ インコーポレイテッド |
Ras阻害剤
|
US11608346B2
(en)
|
2019-11-04 |
2023-03-21 |
Revolution Medicines, Inc. |
Ras inhibitors
|
MX2022005359A
(es)
|
2019-11-04 |
2022-06-02 |
Revolution Medicines Inc |
Inhibidores de ras.
|
MX2022005525A
(es)
|
2019-11-08 |
2022-06-08 |
Revolution Medicines Inc |
Compuestos de heteroarilo bicíclicos y usos de estos.
|
MX2022005726A
(es)
|
2019-11-14 |
2022-06-09 |
Amgen Inc |
Sintesis mejorada del compuesto inhibidor de g12c de kras.
|
TW202132296A
(zh)
|
2019-11-14 |
2021-09-01 |
美商安進公司 |
Kras g12c抑制劑化合物之改善的合成
|
WO2021108683A1
(en)
|
2019-11-27 |
2021-06-03 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
TW202140011A
(zh)
|
2020-01-07 |
2021-11-01 |
美商銳新醫藥公司 |
Shp2抑制劑給藥和治療癌症的方法
|
WO2021155006A1
(en)
|
2020-01-31 |
2021-08-05 |
Les Laboratoires Servier Sas |
Inhibitors of cyclin-dependent kinases and uses thereof
|
IL301062A
(en)
|
2020-09-03 |
2023-05-01 |
Revolution Medicines Inc |
Use of SOS1 inhibitors to treat malignancies with SHP2 mutations
|
TW202227460A
(zh)
|
2020-09-15 |
2022-07-16 |
美商銳新醫藥公司 |
Ras抑制劑
|
AU2021409816A1
(en)
|
2020-12-22 |
2023-07-06 |
Qilu Regor Therapeutics Inc. |
Sos1 inhibitors and uses thereof
|
WO2022235864A1
(en)
|
2021-05-05 |
2022-11-10 |
Revolution Medicines, Inc. |
Ras inhibitors
|
CN117500811A
(zh)
|
2021-05-05 |
2024-02-02 |
锐新医药公司 |
共价ras抑制剂及其用途
|
KR20240017811A
(ko)
|
2021-05-05 |
2024-02-08 |
레볼루션 메디슨즈, 인크. |
암의 치료를 위한 ras 억제제
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
TW202340214A
(zh)
|
2021-12-17 |
2023-10-16 |
美商健臻公司 |
做為shp2抑制劑之吡唑并吡𠯤化合物
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
WO2024081916A1
(en)
|
2022-10-14 |
2024-04-18 |
Black Diamond Therapeutics, Inc. |
Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
|